Navigation Links
InspireMD Reports Financial Results For Period Ended March 31, 2013
Date:5/8/2013

BOSTON and TEL AVIV, Israel, May 8, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced financial results for the three month period ended March 31, 2013, the third quarter of its 2013 fiscal year.

Revenue for the period increased by 33% over the March 31, 2012 quarter, reflecting the impact of several new marketing initiatives leveraging positive validation from the MASTER I trial of the Company's MGuard™ Embolic Protection Stent (EPS™) published in the November 6, 2012 edition of the peer-reviewed Journal of American College of Cardiology (JACC), Vol. 60, No. 19. Authors of the study concluded that, "among patients with acute STEMI (ST Segment Elevation Myocardial Infarction) undergoing emergent PCI enrolled in the present multicenter, randomized, controlled trial, the MGuard Embolic Protection Stent (EPS) compared to standard metallic stents resulted in superior rates of epicardial coronary flow and complete STR, with trends present toward reduced microvascular obstruction, infarct size and mortality."

Alan Milinazzo, President and CEO of InspireMD, said, "Since joining the Company on January 3rd, we have made significant progress in key strategic areas of the business. In addition to a solid increase in quarterly revenues, we obtained the CE Mark for our carotid stent and we strengthened our board and executive management team. Momentum continued in April as we re-capitalized the Company, uplisted to the NYSE MKT and received regulatory approval to begin enrolling patients in our MASTER II clinical trial. These achievements represent a very good start to 2013 and we expect to continue to deliver strong results on multiple fronts throughout the year."

Financial Highlights for the Quarter Ended March 31, 2013--Revenue for the quarter ended March 31, 2013 totaled $1.5 million, an increase of 33% over the $1.1 million re
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
2. InspireMD Closes $25 Million Underwritten Public Offering
3. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
4. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
5. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
6. InspireMD Reports Results for Period Ended Dec. 31, 2012
7. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
8. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
9. InspireMD Reports Results For Period Ending Sept. 30, 2012
10. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
11. InspireMD to Present at Harvard Investors Group on June 27 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CardioVascular Institute enrolled the first patient in Pennsylvania ... in a trial assessing the safety and effectiveness ... main artery of the leg. The new stent allows for ... stent fracture or re-narrowing after the stent is placed. ... the BioMimics 3D Stent System and will enroll 280 subjects ...
(Date:8/27/2015)...  Lightwave Logic, Inc. (OTCQB: LWLG), a technology ... Generation Photonic Devices and Non-Linear Optical Polymer Materials ... data communications and optical computing, announced today that ... to the Company,s Board of Directors. ... is widely recognized with wide-ranging experience across many ...
(Date:8/27/2015)... SAN FRANCISCO, Calif. , Aug. 27, 2015 ... Probody™ therapeutics for the treatment of cancer, today ... a member of the company,s Board of Directors, ... formerly led immuno-oncology at Eli Lilly and AstraZeneca, ... the first FDA approved checkpoint inhibitor, at Bristol-Myers ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... May 7, 2012  AssureRx Health, Inc. today announced ... the growing number of children and adults diagnosed ... pharmacogenomic test can assist clinicians with important medication ... individual patients tolerate ADHD medications. ...
...  BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, ... announced the completion of a randomized, controlled trial ... product.  ActiPatch uses pulsed electromagnetic field therapy to ... injured tissue. A double blind, ...
Cached Medicine Technology:AssureRx Health Launches Personalized Medicine Test for ADHD 2AssureRx Health Launches Personalized Medicine Test for ADHD 3BioElectronics' ActiPatch Reduces Muscle Soreness in Runners 2
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a ... Patient Education content is ICD-10 ready and available to all clients. All Krames ... code sets, which are more targeted and return a more comprehensive data set ...
(Date:8/27/2015)... ... 27, 2015 , ... Banc Intranets recently entered into a strategic ... both Johnson City, Tenn.-based firms to work synergistically to promote similar products to the ... caters to organizations in the financial, commercial and services sectors. The software, which is ...
(Date:8/27/2015)... ... 2015 , ... Susan Harris and the team at LifeStream Health ... pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch is ... the vaginal tissue, revitalizing cells so they make more collagen, an essential component in ...
(Date:8/27/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and Innovation, ... Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , Ms. ...
(Date:8/27/2015)... ... 2015 , ... Standifer Insurance Group, a full service insurance ... joint charity drive with the Meadow View Elementary School in Alabaster. , A ... many lack the simple supplies necessary for a productive scholastic career. In partnering ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 3
... people seeking active participation in their communities has led researchers to ... engagement can now be considered a distinct retirement role, according to ... (Volume 48, Number 3). , The authors ... at least one day per week that directly impact the ...
... hours for participants in phase II trial , , ... drug called pegloticase lowered levels of uric acid in ... in most patients. , That,s the conclusion of a ... Savient Pharmaceuticals, the company that,s developing the drug. ...
... Trim Holdings,Inc. (Amex: ZTM ) announced today ... private placement subscription agreements pursuant to which we,sold ... for an,aggregate offering price of $2,370,000. Each of ... consists of a $100,000 24-month,senior secured promissory note ...
... overwhelmingly positive, PORTLAND, Ore., Sept. 3 ... doctor to others, according to a,popular online survey ... A,"Member Feedback" feature on the site allows Regence ... providers, including,physicians, dentists, other health care professionals and ...
... Amsterdam, September 3, 2008 A recent study (doi:10.1016/j.clim.2008.06.009) ... of the Clinical Immunology Society (CIS), describes a new ... human cells. The report demonstrates the characterization of specific ... providing information about the role these cells might play ...
... new survey by Medical Economics details surprising statistics on earnings and ... in wages for many doctors accompanied by a decrease in patient ... ... 2008 -- A newly-released 2008 Medical Economics survey focusing on earnings ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: